Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
The authors present here two cases of Parkinson's disease with depression refractory to SSRIs treatment, who experienced a complete remission after replacing the ongoing SSRIs with a serotonin-noradrenalin reuptake inhibitor (SNRI), milnacipran. The case reports suggest that milnacipran may be one of the treatment options for depression in patients with Parkinson's disease who had inadequate response to SSRIs. Further studies are warranted to confirm this observation.
Takahashi
Hitoshi
H
Department of Neuropsychiatry, Akita University School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. hito_takahashi@hotmail.com
Kamata
Mitsuhiro
M
Yoshida
Keizo
K
Higuchi
Hisashi
H
Shimizu
Tetsuo
T
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D010300:Parkinson Disease / Q000150:complications*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D003521:Cyclopropanes; D000078764:Milnacipran; D017367:Selective Serotonin Reuptake Inhibitors